Switching from Reference to Biosimilar Products: An Overview of the European Approach and Real-World Experience So Far
Switching patients from a reference to a biosimilar product has become a primary topic of interest, with different approaches being undertaken by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). In European countries, substitution of a reference medicine with a bi...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
European Medical Journal
2018-09-01
|
| Series: | European Medical Journal |
| Subjects: | |
| Online Access: | https://www.emjreviews.com/rheumatology/article/switching-from-reference-to-biosimilar-products-an-overview-of-the-european-approach-and-real-world-experience-so-far/ |